Intrarectal Xyloglucan Administration Reduces Disease Severity in the Dextran Sodium Sulfate Model of Mouse Colitis

Edward A Ross,1 Madelyn H Miller,2 Allison Pacheco,2 Alicia R Willenberg,1 Justine T Tigno-Aranjuez,2 Kaitlyn E Crawford3 1Department of Internal Medicine, College of Medicine, University of Central Florida, Orlando, FL, USA; 2Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ross EA, Miller MH, Pacheco A, Willenberg AR, Tigno-Aranjuez JT, Crawford KE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	ulcerative colitis dextran sodium sulfate dss xyloglucan tamarind inflammatory bowel disease Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/a75edf4892a34fb3a0f97b17c79006ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a75edf4892a34fb3a0f97b17c79006ae
record_format	dspace
spelling	oai:doaj.org-article:a75edf4892a34fb3a0f97b17c79006ae2021-11-04T19:00:26ZIntrarectal Xyloglucan Administration Reduces Disease Severity in the Dextran Sodium Sulfate Model of Mouse Colitis1178-7023https://doaj.org/article/a75edf4892a34fb3a0f97b17c79006ae2021-11-01T00:00:00Zhttps://www.dovepress.com/intrarectal-xyloglucan-administration-reduces-disease-severity-in-the--peer-reviewed-fulltext-article-CEGhttps://doaj.org/toc/1178-7023Edward A Ross,1 Madelyn H Miller,2 Allison Pacheco,2 Alicia R Willenberg,1 Justine T Tigno-Aranjuez,2 Kaitlyn E Crawford3 1Department of Internal Medicine, College of Medicine, University of Central Florida, Orlando, FL, USA; 2Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, USA; 3Department of Materials Science and Engineering, College of Engineering and Computer Sciences, University of Central Florida, Orlando, FL, USACorrespondence: Edward A RossDepartment of Medicine, College of Medicine, University of Central Florida, 6850 Lake Nona Blvd, Orlando, FL, 32827, USAEmail Edward.ross@ucf.eduBackground: The pathophysiology of inflammatory bowel diseases remains poorly understood and treatment remains suboptimal for many patients. We hypothesize that the inflammatory milieu secondarily prolongs the injury and attenuates healing. We propose primary or adjuvant therapy with biocompatible adhesives to restore a barrier to protect submucosal structures, particularly stem cells.Methods: We used the well-described mouse dextran sodium sulfate (DSS) model of colitis resembling human ulcerative colitis to test the therapeutic efficacy of intrarectal administration of the tamarind plant-derived xyloglucan (TXG) polymer adhesive which underwent extensive analytic characterization. Mice in control, DSS-only, TXG-only, and DSS + TXG groups were studied for gross (weight, blood in stool, length of colon) and multiple histologic parameters.Results: Compared to DSS-only mice, TXG prevented the weight loss, occurrence of blood in the stool and colon shortening, with all those parameters not being statistically different from treatment naïve animals. Histologically, there was dramatic and highly statistically significant reduction in the total inflammatory index and protection from goblet cell loss, cellular infiltration, crypt abscess formation, epithelial erosion, granulation tissue, epithelial hyperplasia crypt irregularity and crypt loss. The TXG purity and characterization were established by nuclear magnetic resonance, infrared spectroscopy, differential scanning calorimetry, and texture analysis.Conclusion: The striking attenuation of disease severity by intrarectal TXG use warrants future investigations of natural bioadhesives with well-established high safety profiles, and which could potentially be derivatized to include therapeutically active moieties for local drug delivery.Keywords: ulcerative colitis, dextran sodium sulfate, DSS, xyloglucan, tamarind, inflammatory bowel diseaseRoss EAMiller MHPacheco AWillenberg ARTigno-Aranjuez JTCrawford KEDove Medical Pressarticleulcerative colitisdextran sodium sulfatedssxyloglucantamarindinflammatory bowel diseaseDiseases of the digestive system. GastroenterologyRC799-869ENClinical and Experimental Gastroenterology, Vol Volume 14, Pp 429-439 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ulcerative colitis dextran sodium sulfate dss xyloglucan tamarind inflammatory bowel disease Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	ulcerative colitis dextran sodium sulfate dss xyloglucan tamarind inflammatory bowel disease Diseases of the digestive system. Gastroenterology RC799-869 Ross EA Miller MH Pacheco A Willenberg AR Tigno-Aranjuez JT Crawford KE Intrarectal Xyloglucan Administration Reduces Disease Severity in the Dextran Sodium Sulfate Model of Mouse Colitis
description	Edward A Ross,1 Madelyn H Miller,2 Allison Pacheco,2 Alicia R Willenberg,1 Justine T Tigno-Aranjuez,2 Kaitlyn E Crawford3 1Department of Internal Medicine, College of Medicine, University of Central Florida, Orlando, FL, USA; 2Immunity and Pathogenesis Division, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, USA; 3Department of Materials Science and Engineering, College of Engineering and Computer Sciences, University of Central Florida, Orlando, FL, USACorrespondence: Edward A RossDepartment of Medicine, College of Medicine, University of Central Florida, 6850 Lake Nona Blvd, Orlando, FL, 32827, USAEmail Edward.ross@ucf.eduBackground: The pathophysiology of inflammatory bowel diseases remains poorly understood and treatment remains suboptimal for many patients. We hypothesize that the inflammatory milieu secondarily prolongs the injury and attenuates healing. We propose primary or adjuvant therapy with biocompatible adhesives to restore a barrier to protect submucosal structures, particularly stem cells.Methods: We used the well-described mouse dextran sodium sulfate (DSS) model of colitis resembling human ulcerative colitis to test the therapeutic efficacy of intrarectal administration of the tamarind plant-derived xyloglucan (TXG) polymer adhesive which underwent extensive analytic characterization. Mice in control, DSS-only, TXG-only, and DSS + TXG groups were studied for gross (weight, blood in stool, length of colon) and multiple histologic parameters.Results: Compared to DSS-only mice, TXG prevented the weight loss, occurrence of blood in the stool and colon shortening, with all those parameters not being statistically different from treatment naïve animals. Histologically, there was dramatic and highly statistically significant reduction in the total inflammatory index and protection from goblet cell loss, cellular infiltration, crypt abscess formation, epithelial erosion, granulation tissue, epithelial hyperplasia crypt irregularity and crypt loss. The TXG purity and characterization were established by nuclear magnetic resonance, infrared spectroscopy, differential scanning calorimetry, and texture analysis.Conclusion: The striking attenuation of disease severity by intrarectal TXG use warrants future investigations of natural bioadhesives with well-established high safety profiles, and which could potentially be derivatized to include therapeutically active moieties for local drug delivery.Keywords: ulcerative colitis, dextran sodium sulfate, DSS, xyloglucan, tamarind, inflammatory bowel disease
format	article
author	Ross EA Miller MH Pacheco A Willenberg AR Tigno-Aranjuez JT Crawford KE
author_facet	Ross EA Miller MH Pacheco A Willenberg AR Tigno-Aranjuez JT Crawford KE
author_sort	Ross EA
title	Intrarectal Xyloglucan Administration Reduces Disease Severity in the Dextran Sodium Sulfate Model of Mouse Colitis
title_short	Intrarectal Xyloglucan Administration Reduces Disease Severity in the Dextran Sodium Sulfate Model of Mouse Colitis
title_full	Intrarectal Xyloglucan Administration Reduces Disease Severity in the Dextran Sodium Sulfate Model of Mouse Colitis
title_fullStr	Intrarectal Xyloglucan Administration Reduces Disease Severity in the Dextran Sodium Sulfate Model of Mouse Colitis
title_full_unstemmed	Intrarectal Xyloglucan Administration Reduces Disease Severity in the Dextran Sodium Sulfate Model of Mouse Colitis
title_sort	intrarectal xyloglucan administration reduces disease severity in the dextran sodium sulfate model of mouse colitis
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/a75edf4892a34fb3a0f97b17c79006ae
work_keys_str_mv	AT rossea intrarectalxyloglucanadministrationreducesdiseaseseverityinthedextransodiumsulfatemodelofmousecolitis AT millermh intrarectalxyloglucanadministrationreducesdiseaseseverityinthedextransodiumsulfatemodelofmousecolitis AT pachecoa intrarectalxyloglucanadministrationreducesdiseaseseverityinthedextransodiumsulfatemodelofmousecolitis AT willenbergar intrarectalxyloglucanadministrationreducesdiseaseseverityinthedextransodiumsulfatemodelofmousecolitis AT tignoaranjuezjt intrarectalxyloglucanadministrationreducesdiseaseseverityinthedextransodiumsulfatemodelofmousecolitis AT crawfordke intrarectalxyloglucanadministrationreducesdiseaseseverityinthedextransodiumsulfatemodelofmousecolitis
_version_	1718444669493313536

Intrarectal Xyloglucan Administration Reduces Disease Severity in the Dextran Sodium Sulfate Model of Mouse Colitis

Ejemplares similares